From first class to third class: Recent upheaval in antiarrhythmic therapy - Lessons from clinical trials

American Journal of Cardiology

Volumn 78, Issue 4 A, 1996, Pages 28-33

  Lazzara, Ralph ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DILTIAZEM; ENCAINIDE; FLECAINIDE; IMIPRAMINE; LIDOCAINE; MEXILETINE; MORACIZINE; PIRMENOL; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TOCAINIDE; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; META ANALYSIS; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SECONDARY PREVENTION; TORSADE DES POINTES;

EID: 0029848068     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00450-X     Document Type: Conference Paper

References (15)

1. Vaughan Williams EM. Classification of antiarrhythmic drugs. In: Sandoe E, Flensted-Jensen E, Olesen KH, eds. Symposium on Cardiac Arrhythmias. Sodertalje, Sweden: AB Astra, 1970:449-472.
2. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-1851.
3. The Cardiac Arrhythmia Suppression Trial Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
4. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW, and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
5. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
6. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1711-1718.
7. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, Dyduszynski A, Maciejewicz J, Zaleska T, Lazarczyk-Kedzia E, Motyka J, Paczkowska B, Sczaniecka O, Yusuf S. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-1062.
8. Waldo AL, Camm AJ, de Ruyter H, Friedman PL, MacNeil DJ, Pitt B, Pratt CM, Schwartz PJ, Veltri EP, and the SWORD Investigators. Preliminary mortality results from the survival with oral d-sotalol (SWORD) trial. (Abstr.) J Am Coll Cardiol 1995 Special Issue:15A.
9. Yusuf S, Teo K. Critical analysis of various approaches to the prevention of sudden death. In: Singh BN, Wellens HJJ, Hiraoka M, eds. Controlling Cardiac Arrhythmias by Electropharmacologic Therapy: To Delay Conduction or to Prolong Refractoriness. Mt Kisco, NY: Futura Publishing, 1993.
10. Mason JW, for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993;329:445-451.
11. Mason JW, for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-458.
12. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993;72:280-287.
13. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115-172.
14. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993;72(suppl):44A-50A.
15. Julian DG, Jackson FS, Prescott RJ, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;i:1142-1147.